Is There A Point To Subgroup Analyses Of STABILITY?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Co-chair of the failed study says secondary endpoints adding revascularization and unstable angina to the hard MACE primary endpoint show “hypothesis-generating” findings, but discussant Kastelein questions the prospects for any more trials to test those hypotheses.
You may also be interested in...
GSK’s Darapladib Poised To Become Latest Cardiovascular Outcomes Casualty
Company announces that Lp-PLA2 inhibitor darapladib fails Phase III STABILIITY outcomes study, the latest in a string of pharma CV failures.
Keeping Track: Tumor-Agnostic Approval For Novartis; Submissions From Krystal, Menarini, And Astellas
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Acer’s ‘Misunderstood Drugs’ Strategy Faces Regulatory Hurdles
Acer repurposes drugs with available data (like a 40-year-old European antihypertensive) into rare disease treatments (like Edsivo for vascular Ehlers-Danlos syndrome), but approval remains elusive, with a CRL for ACER-001 just as Edsivo is poised to enter a new clinical trial, armed with a new breakthrough designation. The Pink Sheet delves into regulatory history and strategy with CEO Chris Schelling.